September 3, 2010 | Pfizer plans to acquire FoldRx, a Massachusettes-based biotech whose lead drug candidate has orphan drug designation in both the US and EU. The drug targets ATTR-PN, a rare disease affects the liver and generally kills patients 9 to 11 years after onset. FoldRx has already submitted the to regulators in the EU and has Fast Track designation in the US. The acquisition follows Pfizer's creation of an Orphan and Genetic Diseases Research Unit earlier this year. Boston Business Journal